Nirsevimab is a long-acting RSV-specific monoclonal antibody recommended for some infants as part of the RSV Mother and Infant Protection Program (RSV-MIPP).
The RSV vaccine Abrysvo is funded on the National Immunisation Program for pregnant people from 28 weeks’ gestation. Nirsevimab is recommended for infants:
- whose mother did not receive an RSV vaccine during pregnancy
- born within two weeks of Abrysvo being administered
- at increased risk of severe RSV
- born to mothers with severe immunosuppression.
Nirsevimab programs are already underway in some jurisdictions. The South Australian, Tasmanian and Victorian programs will start on 1 April 2025.
Catch-up programs for infants born before the nirsevimab program commences vary between jurisdictions. Also, note that some infants are recommended to receive nirsevimab in their second RSV season. Read the National Centre for Immunisation Research and Surveillance’s (NCIRS) document State and territory nirsevimab (Beyfortus) infant program summary 2025 for more information.
Learn more on MVEC’s immmunisation reference page, MVEC: Respiratory syncytial virus (RSV).